MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Boehringer Ingelheim announced the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies.

Eli Lilly and Company (NYSE: LLY) has been named to the 2011 NAFE Top 50 Companies for Executive Women by the National Association for Female Executives (NAFE).

GlaxoSmithKline (GSK) announced positive, top-line results of the ADVANCE-Parkinson's Disease (PD) Phase III clinical study, conducted by Impax Pharmaceuticals, of IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD) in advanced PD patients experiencing motor fluctuations.

Amgen (Nasdaq: AMGN) announced that the company will donate $1 million to Japanese disaster relief efforts. Amgen and the Amgen Foundation will distribute the funds to both Direct Relief International and International Medical Corps to bring basic needs and vital health services to those affected in Japan.

Abbott (NYSE: ABT), through its philanthropic foundation the Abbott Fund, is providing $3 million (245 million yen) to support immediate relief efforts in response to the devastating earthquake and tsunami in Japan.

OncoTrack, an international consortium of over 60 scientists, managed by Bayer HealthCare Pharmaceuticals and the Max Planck Institute for Molecular Genetics, has launched one of Europe's largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer.

GlaxoSmithKline plc (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that the U.S. Food and Drug Administration (FDA) has approved Benlysta® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.